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AbstrAct
Objective 10-year cardiovascular disease (CVD) risk 
scores are calculated using algorithms, including 
Framingham (worldwide) and QRISK2 (UK). Recently, an 
updated QRISK3 model was introduced, which considers 
new variables including SLE and steroid prescription, 
not included in QRISK2 and Framingham algorithms. We 
sought to determine the extent to which QRISK3 improves 
identification of high-risk patients with SLE and whether 
the score relates to standard and novel markers of SLE-
specific endothelial dysfunction.
Methods Framingham and QRISK2/3 scores were 
calculated in patients with SLE  (n=109) and healthy 
controls (n=29) using clinical measures. In a smaller 
cohort (n=58), markers of inflammation and endothelial 
dysfunction, including CD144+ endothelial microvesicles 
(EMVs), triglycerides, vascular cell adhesion molecule 
(VCAM) and high-sensitivity C reactive protein (hsCRP) 
were quantified by flow cytometry and ELISA, respectively.
Results Patients with SLE demonstrated significantly higher 
QRISK3 scores than controls (5.0%vs0.3%, p<0.001). 21/109 
patients with SLE (19%) and 24/109(22%) were newly 
identified as being at high risk of a CV event when using 
QRISK3 versus QRISK2 (29vs8patients) and QRISK3 versus 
Framingham (29vs5patients; p<0.001), respectively. These 
‘new QRISK3’ patients with SLE were more likely to have 
lupus nephritis, be anticardiolipin antibody positive, currently 
prescribed corticosteroids, had a higher Body Mass Index and 
systolic blood pressure (BP) than low-risk patients with SLE. 
Rates of antiplatelet (8/21) and statin use (5/21) were low in 
the new QRISK3 group. EMVs, hsCRP and triglyceride levels 
were significantly higher in new QRISK3 patientscompared 
with low-risk patients with SLE (p<0.05). Furthermore, pulse 
wave velocity and VCAM were significantly elevated in all 
high versus low QRISK3 patients.
Conclusions QRISK3 captures significantly more patients 
with SLE with an elevated 10-year risk of developing 
CVD, which is associated with measures of endothelial 
dysfunction; EMVs and systolic BP. The adoption of QRISK3 
will enhance management of CVD risk in patients with SLE 
for improved outcome.
IntROduCtIOn
Cardiovascular disease (CVD) risk is evalu-
ated using algorithms, comprising variables 
(eg, age, blood pressure (BP) and choles-
terol) that can have an independent or a 
synergistic impact on CVD risk1 to identify 
asymptomatic individuals and initiate CVD 
risk management. Patients with SLE have a 
fivefold increased risk of myocardial infarc-
tion compared with healthy controls,2 rising 
to fifty-fold in younger women (35–44years).3 
Traditional risk algorithms (eg, Framingham) 
show only marginal differences between SLE 
and controls, and thus underestimate CVD 
risk of a patient with SLE.2 SLE-related factors 
(disease activity, immunological factors and 
medications) are believed to play a substantial 
role in CVD risk and poorer cardiovascular 
outcomes following a CV event.4 5
Strategies to more accurately predict CVD 
risk in SLE have involved modification of tradi-
tional calculators by doubling the score and 
proposing SLE-specific risk tools6; however, 
they are not in regular clinical use since risk 
assessment and treatment is provided by 
primary care physicians.
Enhanced understanding of the pathophys-
iology of subclinical atherosclerosis and more 
sensitive CVD biomarkers (eg, high-sensitivity 
C reactive protein; hsCRP) may help iden-
tify those at high risk. Endothelial dysfunc-
tion, as assessed by endothelial microvesicle 
(EMV) release or aortic pulse wave velocity 
(PWV), have also shown promise as potential 
biomarkers. We have previously demonstrated 
elevated levels of EMVs in patients with SLE, 
which were reduced with immunosuppres-
sion,4 reflecting their potential to monitor 
endothelial activation.
Since 2008, the QRISK2 algorithm has been 
used in the UK to calculate the likelihood of a 
major cardiovascular event over the following 
10-year period. A score of≥10% is deemed to 
be ‘high risk’, indicating the need for clinical 
intervention (National Institute for Health 
and Care Excellence guidelines).7 An updated 
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Table 1 Baseline cardiovascular measures of controls, low risk and newly identified high QRISK3 patients with SLE
Variable Controls (n=29)
Newly identified 
high QRISK3 
patients* (n=21) P values
Low-risk patients 
with SLE (n=80)
Newly identified 
high QRISK3 
patients*(n=21) P values
Age (years),mean±SD 36.66±12.95 42.16±12.36 0.130 38.02±10.68 42.16±12.36 0.155
Female 29(100%) 19(90%) 0.420 78(97%) 19(90%) 0.507
Ethnicity: Caucasian 23(79%) 13(62%) 0.213 58(73%) 13(62%) 0.292
BMI (kg/m2) 22.6(21.3,25.3) 31.8(24.3,37.0) 0.003 25.3(22.2,28.4) 31.8(24.3,37.0) 0.026
BP systolic (mm Hg) 118.0(111.0,130.0) 141.0(127.0,159.0) 0.001 122.0(110.8,128.3) 141.0(127.0,159.0) <0.001
HDL cholesterol (mmol/L) 1.7(1.5,2.0) 1.5(1.3,1.8) 0.037 1.7(1.2,2.0) 1.5(1.3,1.8) 0.222
Non-HDL cholesterol 
(mmol/L) 2.6(2.3,3.2) 3.2(2.5,3.6) 0.115 2.7(2.2,3.2) 3.2(2.5,3.6) 0.053
Type 2 diabetes 0(0%) 3(14%) 1.000 0(0%) 3(14%) 0.008
Rheumatoid arthritis 0(0%) 0(0%) 1.000 5(6%) 0(0%) 0.312
Chronic kidney 
disease(stages3–5) 0(0%) 5(24%) 0.010 3(4%) 5(24%) 0.021
Migraines 3(10%) 1(5%) 0.630 8(10%) 1(5%) 0.681
Severe mental illness 2(7%) 2(9%) 1.000 3(4%) 2(9%) 0.277
Current smoker 4(14%) 6(29%) 0.286 15(19%) 6(29%) 0.368
Antihypertensive 3(10.34%) 15(71%) <0.001 13(16%) 14(67%) <0.001
Current oral corticosteroids 0(0%) 21(100%) <0.001 46(58%) 21(100%) <0.001
Variables included in QRISK3 algorithm are shown; severe mental illness inclusive of depression, schizophrenia and bipolar disorder. 
Unless otherwise stated, values are shown as number (percentage) or median (lower, upper quartile). Data were analysed by Mann-
Whitney U and Fisher’s exact tests as appropriate. 
Bold type denotes p<0.05.
*Newly identified high QRISK3 patientsrefers to patients with SLEnewly identified as possessing high cardiovascular risk (≥10%) when 
using QRISK3 vsQRISK2. Patients with SLEidentified as high risk by both algorithms were not included in the analysis (n=8).
BMI, Body Mass Index;BP, blood pressure;HDL, high-density lipoprotein.
QRISK3 algorithm, incorporating additional risk factors 
including SLE, was released in May 2017, becoming the 
first widely used calculator to address SLE-associated CVD 
risk.8 Our aim was to identify (1) differences in CVD risk 
estimates when using QRISK3 compared with QRISK2 
and Framingham algorithms; (2) differences in tradi-
tional CVD risk factors, between newly identified high-risk 
patients with SLE, low-risk patients with SLE and controls; 
(3) SLE-specific factors driving the increased risk; and 
(4) novel biomarkers that could be integrated into future 
algorithms to enhance detection of subclinical CVD.
MethOds
Patients
Patients with SLE(n=109; 1997 American College of 
Rheumatology criteria)9 and healthy controls (n=29) 
were recruited from the rheumatology department in the 
Manchester Royal Infirmary.  See online supplementary 
information for clinical/laboratory assessments, CVD risk 
identification and statistical analysis.
Results
demographics
Patients with SLE were, on average, 4years older than 
controls, with no differences detected in gender, ethnicity 
or traditional cardiovascular risk factors (systolic pressure 
levels, high-density lipoprotein (HDL)/non-HDL choles-
terol, rates of smoking and diabetes; online supplemen-
tary file 1).
CVd risk identification
Patients with SLE had higher absolute Framingham 
(2.2%vs1.2%, p=0.013), QRISK2 (1.7%vs0.3%, p=0.001) 
and QRISK3 (5.0%vs0.3%, p<0.001) scores than controls. 
The QRISK3 score was higher in patients with SLE 
compared with QRISK2 and Framingham models. In total, 
5(4.6%) and 8(7%) patients with SLE were designated as 
high risk by Framingham and QRISK2 algorithms, respec-
tively, rising to 29(27%) patients with QRISK3 (p<0.001). 
QRISK3 identified 21 additional patients (19%) as high 
risk who would have otherwise been designated as low 
risk of CVD using QRISK2 (new QRISK3 group), rising to 
24 extra patients when using the Framingham algorithm.
Since SLE is not included in QRISK2 or Framingham 
models, SLE was removed from the calculation to deter-
mine whether additional patients would still be identified. 
Three patients with SLE were newly identified by QRISK3 
versus QRISK2. In the control group, no differences were 
observed between any risk algorithm.
differences in CVd risk factors
The new QRISK3 group had a significantly higher Body 
Mass Index (BMI), systolic BP, lower HDL cholesterol 
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Table 2 Clinical and immunological measures of low risk and new QRISK3 patients
Variable* Low-risk patients with SLE New QRISK3 group P values
Disease duration (years) 13.0(8.0,19.0) 12.0(6.7,15.0) 0.326
ACR criteria: malar rash 35(70%) 14(67%) 0.785
ACR criteria: discoid rash 25(50%) 6(29%) 0.120
ACR criteria: photosensitivity 34(68%) 14(67%) 1.000
ACR criteria: oral ulcers 36(72%) 14(67%) 0.777
ACR criteria: serositis 15(30%) 6(29%) 1.000
ACR criteria: arthritis 44(88%) 14(67%) 0.047
ACR criteria: renal disorder 19(38%) 14(67%) 0.038
ACR criteria: neurological disorder 4(8%) 2(9%) 1.000
ACR criteria: haematological disorder 30(60%) 11(52%) 0.605
ACR criteria: immunological disorder 39(78%) 14(67%) 0.375
ACR criteria: ANA-positive† 46(94%) 18(86%) 0.352
Anti-dsDNA antibodies† 15(30%) 9(43%) 0.429
Anticardiolipin antibodies† 4(8%) 7(33%) 0.027
Low C3+lowC4 levels† 5(10%) 2(9%) 1.000
Current oral corticosteroids 19(38%) 21(100%) <0.001
Prednisolone dose (mg/day) 7.5(5.0,11.3) 10(5.5,15.0) 0.304
Current immunosuppressive use 29(58%) 13(62%) 0.582
Current antimalarial use 36(72%) 17(81%) 0.556
SLEDAI-2K (n=58) 2.5(0.25,4.0) 3.0(2.0,4.5) 0.444
BILAG-2004 (n=58) 1.5(0.25,6.75) 5.5(0.0,9.3) 0.542
CD144+EMVs/mL (n=58) 1.51×106(1.05×106,2.23×106) 2.45×106(2.05×106,5.56×106) 0.019
Pulse wave velocity(n=58) 7.00(6.00,7.70) 7.60(7.05,9.50) 0.110
Triglycerides (mg/dL) (n=58) 0.80(0.60,1.30) 1.45(1.05,2.53) 0.022
hsCRP (mg/L) (n=58) 0.89(0.54,3.01) 6.70(4.47,8.18) <0.001
VCAM-1 (mg/L) (n=58) 420.76(349.23,492.32) 502.65(439.72,567.21) 0.099
BLyS (mg/L) (n=58) 0.48(0.35,0.61) 0.61(0.39,0.72) 0.534
*n=71 unless otherwise stated.
†Indicated by laboratory reference range. Data were analysed by Mann-Whitney U and Fisher’s exact tests.
ACR, American College of Rheumatology;BILAG-2004, British Isles Lupus Assessment Group Disease Activity Index;BLyS, 
B-lymphocyte stimulator;C3, complement component C3;C4, complement component C4;dsDNA, double-stranded DNA;EMV, 
endothelial microvesicle;hsCRP, high-sensitivity C reactive protein;SLEDAI-2K, SLE Disease Activity Index 2000;VCAM, vascular cell 
adhesion molecule-1.
levels, were more likely to have chronic kidney disease 
(CKD) and to be taking oral corticosteroids than controls 
(table 1).
Despite significantly higher rates of antihypertensive 
use in the new QRISK3 group, newly identified patients 
had significantly higher systolic BP levels, glucocorticoid 
use, CKD, BMI and type 2 diabetes than low-risk patients 
(table 1). Similar results were obtained when comparing 
the new QRISK3 versus Framingham low-risk groups.
differences in sle-related factors
To determine the key SLE-specific factors that may be 
driving the increased CVD risk, we investigated a cohort 
for whom more detailed clinical data were available 
(n=71). Lupus nephritis (p=0.038), elevated levels of anti-
cardiolipin antibodies (p=0.027) and current steroid use 
were higher (p<0.001) in the new QRISK3 group (table 2). 
No differences in disease activity, rates of antimalarial use 
or additional immunosuppressive therapy were identified 
between new QRISK3 and low-risk patients (table 1).
Of the newly identified patients, 15(71.4%) were on anti-
hypertensives. The mean BP for those patients was higher 
than the recommended treatment thresholds at 147/97; 
five(23.8%) patients were on a statin, eight(38.1%) were 
on an antiplatelet and six(28.6%) were smokers.
Associations between endothelial dysfunction, inflammation 
and QRIsK
EMVs correlated positively with QRISK3 score across all 
participants (r=0.332, p=0.001) but not with QRISK2 
or Framingham scores. New QRISK3 patients demon-
strated higher levels of circulating EMVs than low-risk 
patients (p=0.019, table 2; figure 1). PWV did not distin-
guish between the new QRISK3 and low-risk groups; 
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Figure 1 Measures of endothelial activation/dysfunction are associated with QRISK3. Increased pulse wave velocity (PWV; 
p=0.017), EMVs (p=0.024), VCAM-1 (p=0.042), triglycerides (p=0.015) and hsCRP (p=0.001) levels are associated with high 
QRISK3 score. Newly identified patients also demonstrate significantly higher EMVs (p=0.020), triglycerides (p=0.016) and 
hsCRP levels (p<0.001). Data represent patients with SLE: low QRISK3 (n=49), high QRISK3 (n=11), low risk (n=49), newly 
identified (n=8). Data were analysed by Mann-Whitney U test. EMV, endothelial microvesicle; hsCRP, high-sensitivity C reactive 
protein; TG, triglyceride; VCAM-1, vascular cell adhesion molecule-1.
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however, both PWV and EMVs were higher in all high 
vs low QRISK3 groups (p<0.05; figure 1). Triglycerides 
and hsCRP were also higher in new QRISK3 patients 
compared with low risk, with no difference in VCAM and 
B-lymphocyte stimulator (BLyS) levels, although VCAM 
was significantly higher in all high-risk versus low-risk 
QRISK3 groups (figure 1). No differences were detected 
between high and low QRISK2 groups with regard to 
PWV, EMVs, VCAM or BLyS levels (data not shown).
dIsCussIOn
QRISK3 identified three times as many patients with high 
CVD risk than QRISK2, rising to five times with Fram-
ingham, many of whom were not on appropriate risk 
factor modification treatment. Detection of CVD risk in 
SLE is complex, with traditional tools failing to identify 
at-risk patients, while SLE-specific tools are not widely 
incorporated in clinical practice. Our findings suggest 
that the QRISK3 tool will successfully identify more 
patients with SLE with high risk of CVD since it can be 
used easily in primary care, where the majority of CVD 
risk management is conducted in the UK, while providing 
an SLE-inclusive risk similar to specialised SLE calcula-
tors.10
When SLE was removed from the QRISK3 calculation, 
three patients were newly identified as high risk, indi-
cating that SLE is the main driver of increased risk. Both 
renal disease and corticosteroid use are known to impact 
on atherosclerosis along with the traditional risk factors 
including diabetes, BMI and hypertension5; however, 
40% of the variation in time to diagnosis of CVD remains 
unexplained by the QRISK3 algorithm. Therefore, addi-
tional measures of CV health/risk may further enhance 
detection of subclinical atherosclerosis.
The newly identified QRISK3 group exhibited elevated 
levels of anticardiolipin antibodies, EMVs and hsCRP; 
all are further predictors of endothelial dysfunction and 
cardiovascular events in autoimmune disease.4 11 EMVs, 
containing bioactive molecules, are released into the 
bloodstream following endothelial activation, such as that 
occurring under conditions of inflammation.12 The role 
of EMVs in cell signalling, damaging or protective, in SLE 
remains to be elucidated and is under investigation in 
our laboratory. EMVs are potential biomarkers of vascular 
disease since they are elevated in a number of CVD-re-
lated conditions, including SLE,4 12 13 and are modulated 
by lipid-lowering and immunosuppressive therapies.4 14 
Incorporation of EMVs, hsCRP and anticardiolipin anti-
bodies into future derivations of risk tools may enhance 
detection of subclinical CVD.
BP control was suboptimal in high-risk patients and 
triglyceride levels distinguished newly identified QRISK3 
patients from low-risk patients, while antiplatelet and 
statin use was low in the new QRISK3 group. Thus, the 
QRISK3 tool will highlight to primary care physicians 
a previously unrecognised cohort of patients with SLE 
who would benefit from more aggressive management 
strategies—tighter BP control, use of statins and anti-
platelets—to reduce overall CVD risk. These drugs have 
also been shown to improve endothelial function,15 a 
key initiating factor of CVD, and can reduce EMV levels, 
reflecting a reduction in endothelium activation.14
Our study has some limitations. As in any SLE study, a 
high proportion of patients are women, limiting generalis-
ability of our observations to male patients. The relatively 
low patient numbers may have limited identification of 
SLE-related factors as an influence in the newly identified 
high-risk group, while we were unable to assess the effect 
of change in therapy on altering the QRISK score. Future 
work will follow a larger cohort prospectively and validate 
the benefit of incorporating novel biomarkers into future 
CVD risk algorithms.
We have demonstrated that QRISK3 enhances CVD 
risk detection in patients with SLE, with more than 
20% of patients being newly identified as at high risk of 
CVD, in comparison with the QRISK2 and Framingham 
algorithms, with potential for risk factor modification. 
Anticardiolipin antibody positivity and measures of endo-
thelial dysfunction are key determinants of this enhanced 
risk. The new QRISK3 algorithm will enhance physicians’ 
ability to detect CVD risk and alert them to treat modifi-
able risk factors to improve patient outcomes.1 23451
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